Suppr超能文献

试验参与者的试验结果摘要的内容、方式、时间和人员:RECAP 项目的利益相关者知情指导。

What, how, when and who of trial results summaries for trial participants: stakeholder-informed guidance from the RECAP project.

机构信息

Health Services Research Unit, University of Aberdeen, Aberdeen, UK.

Patient Partner, University of Aberdeen, Aberdeen, UK.

出版信息

BMJ Open. 2022 Mar 25;12(3):e057019. doi: 10.1136/bmjopen-2021-057019.

Abstract

OBJECTIVE

To generate stakeholder informed evidence to support recommendations for trialists to implement the dissemination of results summaries to participants.

DESIGN

A multiphase mixed-methods triangulation design involving Q-methodology, content analysis, focus groups and a coproduction workshop (the REporting Clinical trial results Appropriately to Participants project).

SETTING

Phase III effectiveness trials.

PARTICIPANTS

A range of participants were included from ongoing and recently completed trials, public contributors, trialists, sponsors, research funders, regulators, ethics committee members.

RESULTS

Fewer than half of the existing trial result summaries contained information on the clinical implications of the study results, an item deemed to be of high importance to participants in the Q-methodology study. Priority of inclusion of a thank you message varied depending on whether considering results for individuals or populations. The need for personally responsive modes of sharing trial result summaries was highlighted as important. Ideally, participants should be the first to know of the results with regard to the timing of sharing results summaries but given this can be challenging it is therefore important to manage expectations. In addition to patients, it was identified that it is important to engage with a range of stakeholders when developing trial results summaries.

CONCLUSIONS

Results summaries for trial participants should cover four core questions: (1) What question the trial set out to answer?; (2) What did the trial find?; (3) What effect have the trial results had and how will they change National Health Service/treatment?; and (4) How can I find out more? Trial teams should develop appropriately resourced plans and consult patient partners and trial participants on how 'best' to share key messages with regard to content, mode, and timing. The study findings provide trial teams with clear guidance on the core considerations of the 'what, how, when and who' with regard to sharing results summaries.

摘要

目的

生成利益相关者知情的证据,以支持向试验人员提出的建议,即向参与者传播研究结果摘要。

设计

一个涉及 Q 方法、内容分析、焦点小组和合作生产研讨会(适当向参与者报告临床试验结果的项目)的多阶段混合方法三角测量设计。

设置

第三阶段有效性试验。

参与者

包括正在进行和最近完成的试验、公众贡献者、试验人员、赞助商、研究资助者、监管机构、伦理委员会成员在内的各种参与者。

结果

现有的试验结果摘要中,不到一半的摘要包含了研究结果的临床意义信息,这是 Q 方法研究中被认为对参与者非常重要的一项。致谢信息的纳入优先级取决于考虑的是个体还是人群的结果。突出强调了以个人响应的方式共享试验结果摘要的重要性。理想情况下,应让参与者首先了解有关分享结果摘要的时间的结果,但由于这可能具有挑战性,因此管理期望非常重要。除了患者之外,在制定试验结果摘要时,还需要与一系列利益相关者进行接触。

结论

试验参与者的结果摘要应涵盖四个核心问题:(1)试验旨在回答什么问题?;(2)试验发现了什么?;(3)试验结果产生了什么影响,以及它们将如何改变国民保健服务/治疗?;以及(4)我如何了解更多信息?试验团队应制定资源充足的计划,并就如何“最佳”以内容、模式和时间的方式向患者伙伴和试验参与者传达关键信息进行咨询。研究结果为试验团队提供了有关共享结果摘要的“什么、如何、何时和谁”的核心考虑因素的明确指导。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验